Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WIGRETTES vs CAFERGOT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.
Ergotamine is a serotonin (5-HT1B/1D) receptor agonist that causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation. Caffeine is a methylxanthine that enhances ergotamine absorption and may contribute to vasoconstriction.
Smoking cessation therapy,Relief of nicotine withdrawal symptoms
Acute treatment of migraine headaches with or without aura,Acute treatment of cluster headache episodes
1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.
1 to 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack or 10 tablets per week. Alternatively, 1 rectal suppository (ergotamine tartrate 2 mg and caffeine 100 mg) at onset, repeat once after 1 hour if needed, maximum 2 suppositories per attack or 5 per week.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment.
2.5-3.9 hours (ergotamine); clinical context: t1/2 may be prolonged in hepatic impairment.
Primarily hepatic via CYP2A6 and CYP2B6; also metabolized by aldehyde oxidase and N-glucuronidation.
Primarily hepatic via CYP3A4; ergotamine is extensively metabolized, and caffeine is metabolized via CYP1A2.
Renal excretion of unchanged drug accounts for 50-60% of the dose; biliary/fecal elimination accounts for 20-30%; remainder metabolized.
Primarily hepatic metabolism and biliary excretion; less than 5% excreted unchanged in urine. Fecal elimination accounts for most of the administered dose.
90-95% bound to albumin and alpha-1-acid glycoprotein.
98-99% bound to plasma proteins, primarily albumin.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution.
1.1-2.0 L/kg; clinical meaning: extensive tissue distribution, particularly into liver and spleen.
Oral bioavailability is 60-80%; intramuscular bioavailability is 90-100%.
Oral: <5% due to extensive first-pass metabolism; Sublingual: approximately 15-20%; Rectal: approximately 20-30%.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Contraindicated in severe renal impairment. In moderate renal impairment (e GFR 30-59 m L/min/1.73 m²): use with caution; dose reduction not specifically defined but monitor for adverse effects. Mild impairment (e GFR ≥60 m L/min/1.73 m²): no adjustment needed.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 1 mg maximum twice daily. Child-Pugh Class C: Avoid use (not recommended).
Contraindicated in Child-Pugh Class C. Child-Pugh Class A: no adjustment; Class B: use with caution, reduce dose by 50% and monitor. No specific dose recommendations from manufacturer; clinical judgment advised.
Not approved for patients under 18 years of age.
Not recommended for use in pediatric patients due to risk of ergotism and lack of safety data. No established weight-based dosing.
No specific dose adjustment; monitor for adverse effects due to potential age-related decreased renal function.
Use with caution due to increased risk of ergotism, renal/hepatic impairment, and drug interactions. Lower initial dose (e.g., 1 tablet) and careful monitoring. Avoid in patients over 65 with significant vascular disease.
None
Serious and/or life-threatening peripheral ischemia has been associated with coadministration of ergotamine with potent CYP3A4 inhibitors (including protease inhibitors, macrolide antibiotics, and azole antifungals).
Risk of nicotine toxicity if used while smoking; caution in cardiovascular disease, hypertension, diabetes, hyperthyroidism, pheochromocytoma; may cause allergic reactions including angioedema; pregnancy category D.
Risk of ergotism (ischemia, gangrene) with prolonged use or overdosage,May cause vasospastic reactions, including coronary artery vasospasm and myocardial infarction,Rebound headache (medication overuse headache) with frequent use,Caffeine withdrawal may exacerbate headaches,Avoid concurrent use with potent CYP3A4 inhibitors
Hypersensitivity to nicotine or any component; nonsmokers; immediate post-myocardial infarction period; life-threatening arrhythmias; severe or worsening angina pectoris.
Peripheral vascular disease,Coronary artery disease,Hypertension (uncontrolled),Sepsis,Severe hepatic or renal impairment,Pregnancy (Category X),Breastfeeding,Concurrent use of potent CYP3A4 inhibitors
No known food interactions. Avoid concurrent use of retinoid creams or other exfoliating agents that may increase skin sensitivity.
Avoid excessive caffeine intake (e.g., coffee, tea, cola, energy drinks) as Cafergot contains caffeine and may cause additive stimulation or toxicity. Limit caffeine to no more than 200 mg per day during treatment.
WIGRETTES contains nicotine, which is a known teratogen. First trimester exposure is associated with increased risk of spontaneous abortion, preterm birth, and low birth weight. Second and third trimester exposure can lead to reduced fetal growth, placental complications (e.g., abruption), and potential neurobehavioral effects. The risk is dose-dependent and compounded by maternal smoking.
FDA Category X. First trimester: ergotamine is a potent vasoconstrictor and uterine stimulant, associated with increased risk of spontaneous abortion, congenital anomalies (including micrognathia, microphthalmia, cleft palate, and limb defects). Second and third trimesters: continued risk of uteroplacental insufficiency, intrauterine growth restriction, preterm labor, and fetal distress due to vasoconstriction and increased uterine tone.
Nicotine is excreted into breast milk with a milk-to-plasma ratio of approximately 2.9. Concentrations can exceed maternal serum levels. Nursing infants are at risk for nicotine absorption leading to irritability, sleep disturbances, and reduced milk intake. Breastfeeding is generally discouraged during nicotine replacement therapy; if used, timing of patches should minimize infant exposure (e.g., remove at night).
Contraindicated during breastfeeding. Ergotamine reduces prolactin secretion and may suppress lactation. It is excreted into breast milk; M/P ratio not established. Reported infant adverse effects include vomiting, diarrhea, and seizures. Risk of vasospasm and ergotism in the infant.
Pregnancy increases nicotine clearance by approximately 60%, potentially reducing efficacy of standard doses. Higher doses of nicotine replacement therapy may be required to achieve therapeutic effect and prevent withdrawal. However, safety of high-dose NRT in pregnancy is not established. Dose should be individualized based on maternal smoking history and withdrawal symptoms.
Contraindicated in pregnancy; no dosing adjustments recommended. Use is not safe; alternative therapy should be sought.
Wigrettes are wax-based hair removal products containing depilatory agents like calcium thioglycolate. For scalp use only; avoid contact with eyes and broken skin. Perform a patch test 24 hours prior to first use. Do not use on irritated or sunburned skin. Overuse may cause chemical burns or allergic contact dermatitis. Duration of application time is critical: typically 5-10 minutes, do not exceed 15 minutes. Remove with a wooden spatula in direction of hair growth. Neutralize residue with water or mild soap.
Cafergot is ergotamine-caffeine combination for acute migraine. Avoid in pregnancy, uncontrolled hypertension, CAD, and peripheral vascular disease. Maximum dose: 6 tablets per attack or 10 tablets per week. Use at first sign of migraine. Not for prophylaxis. Can cause ergotism with prolonged use. Monitor for signs of ischemia.
Read all directions before use.,Do a patch test on a small area of skin 24 hours before use.,Apply only to clean, dry scalp hair; not for eyebrows, eyelashes, or body hair.,Avoid contact with eyes, nose, and mouth. If contact occurs, rinse with plenty of water.,Do not use on sunburned, broken, or irritated skin.,Set a timer; do not leave on longer than directed (usually 5-10 minutes, max 15 minutes).,Remove product gently with the provided spatula in the direction of hair growth.,Rinse scalp thoroughly with water after removal; do not use soap immediately if irritation occurs.,Do not use more than once every 72 hours.,Store in a cool, dry place away from children.
Take at the first sign of migraine headache for best effect.,Do not take more than 6 tablets per attack or 10 tablets per week.,Avoid use if you are pregnant, breastfeeding, or have high blood pressure, heart disease, or circulation problems.,Seek emergency care if you experience severe stomach pain, chest pain, numbness, tingling, or muscle cramps.,Do not take with other ergotamine drugs or strong CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics).,Store at room temperature, away from heat and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WIGRETTES vs CAFERGOT, answered by our medical review team.
WIGRETTES is a Ergot Alkaloid that works by Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.. CAFERGOT is a Antimigraine Agent (Ergot Alkaloid) that works by Ergotamine is a serotonin (5-HT1B/1D) receptor agonist that causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation. Caffeine is a methylxanthine that enhances ergotamine absorption and may contribute to vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WIGRETTES and CAFERGOT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WIGRETTES is: 1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.. The standard adult dose of CAFERGOT is: 1 to 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack or 10 tablets per week. Alternatively, 1 rectal suppository (ergotamine tartrate 2 mg and caffeine 100 mg) at onset, repeat once after 1 hour if needed, maximum 2 suppositories per attack or 5 per week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WIGRETTES and CAFERGOT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WIGRETTES is classified as Category C. WIGRETTES contains nicotine, which is a known teratogen. First trimester exposure is associated with increased risk of spontaneous abortion, preterm birth, and low birth weight. Se. CAFERGOT is classified as Category C. FDA Category X. First trimester: ergotamine is a potent vasoconstrictor and uterine stimulant, associated with increased risk of spontaneous abortion, congenital anomalies (includi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.